Details of the Drug Reposition

General Information of This Drug (ID: DMOLNHF)

Drug Name
Melphalan   DMOLNHF
Synonyms
Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Refractory plasma cell neoplasm DIS78CK0 N.A. Approved [1]
Leukemia DISNAKFL N.A. Approved [1]
Myeloproliferative neoplasm DIS5KAPA 2A20 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Ovarian cancer DISZJHAP 2C73 Approved [2]
Hematologic disease DIS9XD9A 3C0Z Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Intrahepatic cholangiocarcinoma DIS6GOC8 2C12.10 Phase 3 [3]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [5]
------------------------------------------------------------------------------------
3 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Retinoblastoma DISVPNPB 2D02.2 Investigative [1]
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
------------------------------------------------------------------------------------

References

1 Melphalan FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201379.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04380376) Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia. U.S. National Institutes of Health.
5 Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia